2003•Expert Opinion on Drug SafetyRequires access

Safety of short-acting nifedipine in children with severe hypertension

Joseph T. Flynn

Open publisher page 21 citations

Abstract

Short-acting nifedipine has been abandoned as a treatment for severe hypertension in adults as a result of significant adverse effects. Despite this, it remains a popular choice for the treatment of severe hypertension in children. However, recent publications describing adverse effects of short-acting nifedipine in children similar to those reported in adults, have prompted some experts to question the continued use of this agent in children. In this review, available data on the pharmacology, clinical efficacy and safety of short-acting nifedipine are reviewed, and the advisability of using short-acting nifedipine is reassessed. Although low (< 0.25 mg/kg) doses of short-acting nifedipine may be safe in some hypertensive children, alternative agents that produce more controlled reductions in blood pressure, and that are easier to accurately dose and administer, should probably be chosen for the majority of children with severe hypertension.

About this research paper

What this paper is about

Short-acting nifedipine has been abandoned as a treatment for severe hypertension in adults as a result of significant adverse effects. Despite this, it remains a popular choice for the treatment of severe hypertension in children. However, recent publications describing adverse effects of short-acting nifedipine in children similar to those reported in adults, have prompted some experts to question the continued use of this agent in children. In this review, available data on the pharmacology, clinical efficacy and safety of short-acting nifedipine are reviewed, and the advisability of using short-acting nifedipine is reassessed. Although low (< 0.25 mg/kg) doses of short-acting nifedipine may be safe in some hypertensive children, alternative agents that produce more controlled reductions in blood pressure, and that are easier to accurately dose and administer, should probably be chosen for the majority of children with severe hypertension.

Why it matters

OpenAlex reports 21 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Short-acting nifedipine has been abandoned as a treatment for severe hypertension in adults as a result of significant adverse effects. Despite this, it remains a popular choice for the treatment of severe hypertension in children. However, recent publications describing adverse effects of short-acting nifedipine in children similar to those reported in adults, have prompted some experts to question the continued use of this agent in children. In this review, available data on the pharmacology, clinical efficacy and safety of short-acting nifedipine are reviewed, and the advisability of using short-acting nifedipine is reassessed. Although low (< 0.25 mg/kg) doses of short-acting nifedipine may be safe in some hypertensive children, alternative agents that produce more controlled reductions in blood pressure, and that are easier to accurately dose and administer, should probably be chosen for the majority of children with severe hypertension.

Key concepts: Nifedipine, Medicine, Adverse effect, Blood pressure, Anesthesia, Intensive care medicine, Pharmacology, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Safety of short-acting nifedipine in children with severe hypertension — Research Paper | ScholarLens